Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) PEG Ratio: N/A (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02566 Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd HKSE:02566
20 GF Score
Price HK$5.41
! 1 Warning Sign
View Full Analysis

What is Hangzhou Jiuyuan Genetic Biopharmaceutical Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PE Ratio without NRI is 8.81. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's 5-Year EBITDA growth rate is 0.00%. Therefore, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PEG Ratio or its related term are showing as below:



HKSE:02566's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.91
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co  (HKSE:02566) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co PEG Ratio Related Terms

Hangzhou Jiuyuan Genetic Biopharmaceutical Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co PEG Ratio Chart

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
0.00 0.00 0.00 0.00 0.00

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

HKSE:02566 vs VRTX, REGN, RVMD: PEG Ratio Comparison

For the Biotechnology subindustry, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PEG Ratio falls into.


HKSE:02566
20GF Score
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd HKSE:02566
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Jiuyuan Genetic Biopharmaceutical Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=8.8110749185668/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Business Description

Address No. 23, Eighth Street, Baiyang Street, Qiantang District, Zhejiang Province, Hangzhou, CHN
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score

Get the complete analysis for HKSE:02566

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.41
Price